News
![byondis_facilities_rd](https://pharmaphorum.com/wp-content/uploads/2022/07/byondis_facilities_rd-1.jpg)
Byondis cues up US, EU decisions on breast cancer ADC in 202...
Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight com